WASHINGTON, D.C. (March 5, 2014) — The International Academy of Compounding Pharmacists has responded to a request for submissions from the U.S. Food and Drug Administration (FDA) under the recently enacted Drug Quality and Security Act for Active Pharmaceutical Ingredients (APIs) commonly used by compounding pharmacists to ensure the appropriate treatment of patients.
These APIs, commonly called bulk ingredients, are the raw chemical components used in prescription drugs by manufacturers to produce finished drug products and by compounders to prepare customized patient therapies. Unlike the finished drug products themselves, bulk ingredients are not FDA approved. The IACP, responding to the FDA’s request for interested parties to nominate substances, has submitted a list of more than 2,400 bulk drug substances which are regularly used by compounding pharmacists but which have neither an official United States Pharmacopeia (USP) monograph nor appear to be a component of an FDA-approved drug product.
“The compounding community is working diligently to ensure that the FDA has all the information the agency needs to move forward with the implementation of the Drug Quality and Security Act,” said Pat Stephens, Pharm.D., President of the IACP. “We identified our list of bulk drug substances through a poll of our membership, as well as a review of the latest scientific and medical literature related to compounding pharmacy. Additionally, we are indebted to the IACP Foundation for its tireless work in helping identify as much information about each bulk ingredient as possible through the medical and scientific literature.”
The IACP also submitted for approval the drugs and standards contained within the following official compendia recognized by the FDA but which were not explicitly included in the Drug Quality and Security Act:
The IACP has requested that the FDA’s Pharmacy Compounding Advisory Committee accept and approve all of the bulk drug substances in these compendia as acceptable APIs for the preparation of compounded medications under Section 503A and 503B of the Drug Quality and Security Act, the recently enacted revisions to the Federal Food, Drug, and Cosmetic Act. Section 503B covers compounding pharmacies which are designated by the FDA as “outsourcing facilities” specializing in large-scale production of sterile medications.
The IACP also nominated for 503B outsourcing facilities all drug substances which appear in the current edition of the United States Pharmacopeia/National Formulary. As written, the Drug Quality and Security Act requires those life-sustaining medications to also undergo a review and approval process before an outsourcing facility may use them in their compounding of sterile preparations.
“We respectfully request that the Committee review each of the 2,403 drug substances we have submitted for traditional compounding pharmacies and for 503B outsourcing facilities,” said David G. Miller, R.Ph., the IACP’s Executive Vice President and Chief Executive Officer. “Our Academy looks forward to working with the FDA on this important aspect of the law’s implementation and we hope that the Pharmacy Compounding Advisory Committee works quickly to assure that there are no disruptions in the access to and use of these critical substances in the preparation of medicines that patients need each and every day.”
The IACP’s requests to the FDA may be found online by clicking here.